Cara Therapeutics traded at $3.27 this Thursday March 26th, decreasing $0.02 or 0.61 percent since the previous trading session. Looking back, over the last four weeks, Cara Therapeutics lost 18.05 percent. Over the last 12 months, its price fell by 79.74 percent. Looking ahead, we forecast Cara Therapeutics to be priced at 3.19 by the end of this quarter and at 2.91 in one year, according to Trading Economics global macro models projections and analysts expectations.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.